Tezuka H, Teramoto S, Kaneda M, Henmi R, Murakami N, Shirasu Y
Mutat Res. 1978 May;57(2):201-7. doi: 10.1016/0027-5107(78)90269-5.
Possible mutagenic activity of captan was investigated by in vitro and in vivo cytogenetic studies and by the dominant lethal study in mice. In vitro cytogenetic study with cultured human diploid cells revealed a significant increase in the frequency of cells showing stickiness and a severe mitotic inhibition at concentrations of 3.0 and 4.0 microgram of captan per ml. although no chromosomal aberrations were observed. In in vivo cytogenetic study, no chromosomal aberrations were induced in the bone marrow cells of rats treated orally with captan at a single dose of 500, 1000 or 2000 mg/kg or at five consecutive doses of 200, 400 or 800 mg/kg/day. Dominant lethal study also failed to show any mutation induction after treatment of male mice with daily oral dose of 200 or 600 mg of captan per kg bw for five days.
通过体外和体内细胞遗传学研究以及小鼠显性致死研究，对克菌丹的潜在诱变活性进行了调查。用培养的人类二倍体细胞进行的体外细胞遗传学研究显示，当克菌丹浓度为每毫升3.0和4.0微克时，显示粘连的细胞频率显著增加，且有严重的有丝分裂抑制，尽管未观察到染色体畸变。在体内细胞遗传学研究中，给大鼠单次口服剂量为500、1000或2000毫克/千克的克菌丹，或连续五天每天口服剂量为200、400或800毫克/千克，其骨髓细胞未诱导出染色体畸变。对雄性小鼠每天口服剂量为每千克体重200或600毫克克菌丹，持续五天，显性致死研究也未显示出任何诱变作用。
